CLINICAL_TRIALS
trial_result
· 2019-01-25
Clinical Trial Update: Characteristics of Empagliflozin Initiators
Summary
A completed study describing the characteristics of individuals initiating empagliflozin for Type 2 diabetes mellitus, with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Type 2 Diabetes | Status: COMPLETED | Results posted: 2019-01-25